miR-133a function in the pathogenesis of dedifferentiated liposarcoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Metabolism

Background:

• Dedifferentiated liposarcoma (DDLPS) is an aggressive sarcoma with high recurrence and metastasis rates.
• Previous research indicated significantly underexpressed miR-133a in liposarcoma tissues.
• miR-133a is recognized as a tumor suppressor in various cancers.

Purpose of the Study:

• To investigate the biological and molecular effects of miR-133a underexpression in DDLPS.
• To characterize the role of miR-133a in DDLPS cell behavior and metabolism.

Main Methods:

• Quantitative real-time PCR to measure miR-133a levels in DDLPS tissues and cell lines.
• In vitro studies involving stable transduction of DDLPS cells with a miR-133a vector to assess proliferation, cell cycle, cell death, migration, and metabolism.
• Seahorse Bioanalyzer to measure glycolysis and oxidative phosphorylation (OXPHOS) in vivo using subcutaneous xenograft tumors in mice.

Main Results:

• miR-133a expression was significantly reduced in human DDLPS tissues and cell lines.
• Enforced miR-133a expression reduced cell proliferation, altered cell cycle kinetics, decreased glycolysis, and increased OXPHOS.
• In vivo xenografts showed increased miR-133a expression led to increased OXPHOS but did not affect tumor growth.
• No significant impact on cell death or migration was observed.

Conclusions:

• Loss of miR-133a in DDLPS promotes a metabolic shift, reducing oxidative metabolism and favoring the Warburg effect.
• This metabolic dysregulation, driven by miR-133a loss, is not sufficient to alter DDLPS tumor progression.
• miR-133a may represent a potential therapeutic target for modulating DDLPS metabolism.